Business
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer’s disease by end of 2025 with planned Q2 2026 interim readout Cambridge, Massachusetts, Dec. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targetin
About this update from Promis Neurosciences Inc.
[{"type":"image","alt":"ProMIS Neurosciences Inc.","displaySize":"","headline":null,"caption":"ProMIS Neurosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":125,"url":"https://media.zenfs.com/en/globenewswire.com/cda799201650b516b39828de8c76948b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UIdpZ5Ja0S7N6QhO5P0RBA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cda799201650b516b39828de8c76948b","width":300,"height":125}},"lazy":false},{"type":"text","content":"Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ","length":137,"tagName":"p"},{"type":"text","content":"ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer’s disease by end of 2025 with planned Q2 2026 interim readout","length":133,"tagName":"p"},{"type":"text","content":"Cambridge, Massachusetts, Dec. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD), today announced a publication in the peer-reviewed journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions. entitled, “Relationship between efficacy and preferential targeting of soluble Aβ aggregates.” The paper can be accessed at the following link: http://dx.doi.org/10.1002/trc2.70184.","length":712,"tagName":"p"},{"type":"text","content":"Amyloid beta (Aβ) is known to play a role in the pathogenesis of AD, and certain approved and marketed Aβ-directed antibodies have achieved slowing of cognitive decline in AD. The results and analysis from the study announced today highlight the importance of targeting soluble toxic Aβ aggregates as supported by the observed retrospective correlation between selectivity for soluble toxic oligomers and reported clinical efficacy and the potential for attenuation of amyloid-related imaging abnormalities (ARIA), an adverse side effect of current anti-amyloid antibody therapies.","length":581,"tagName":"p"},{"type":"text","content":"“This new publication reinforces th...